Instructions for Ingaron (Interferon gamma human recombinant)
Release form:
The preparation is in the form of a loose or porous mass of white colour and is hygroscopic.
Lyophilizate for preparation of intranasal administration solution.
Packing 1 bottle.
Composition Ingaron:
Active substances:
Interferon gamma-100,000 IU (5.5±0.5).
Auxiliary substances: mannite
Pharmacotherapy group
MIBP Cytokine.
Release form
Lyophilizate D/R-D/Intranasaln Injection 100 thousand ME: fl 1 or 5 pcs. per package with solvent and dropper cover
Description:
Lyophilizate for preparation of intranasal administration solution 1 fl
interferon gamma 100,000 IU
Solvent: water d/i - 5 ml.
100000 IU - bottles (1) complete with solvent (fl.) and cap-drip of polyethylene - cardboard packs.
100000 IU - bottles (5), complete with solvent (fl.) and cap-drip polyethylene - cardboard packs.
ATC codes
L03AB03 Interferon gamma
Clinical-pharmacological groups / Group affiliation
Immunomodulator
Active substance
interferon gamma
Pharmacotherapy group
MIBP-cytokin
Pharmacological effect:
Interferon gamma is a glycoprotein with a molecular mass of 20-25 kDa and is known as immune interferon. It is derived from human T cells. Recombinant DNA using bacterial cells is now increasingly being used to produce interferon gamma. Two types of interferon gamma-gamma 1a and gamma 2a are known, differing in sequence of amino acids in their chain in 1 and 139 positions. It has a pronounced immunomodulating activity, as it enhances the expression of antigens of the large histocompatibility complex of I and II classes; activates macrophages, enhances the activity of natural killers; reduces expression of subpopulation of B cells, monocytes and eosinophils induced by IL-4; and reduces IgE production; stimulates growth and differentiation of B cells.
Testimony Ingaron:
For Introduction: treatment of chronic viral hepatitis C, chronic viral hepatitis B, HIV/AIDS infection and pulmonary tuberculosis in combination therapy; Prevention of infectious complications in patients with chronic granulomatous disease; Treatment of oncological diseases in complex therapy, as an immunomodulator including in combination with chemotherapy.
For intranasal introduction: Prevention and treatment of influenza (as part of comprehensive therapy); prevention and treatment of avian influenza (as part of a comprehensive therapy).
Method of use, course and dosage:
Used in/m, n/c and intranasally. Dose, method and scheme of application are set individually, depending on indications and tolerability of therapy.
Use in pregnancy and breastfeeding
It is contraindicated for use in pregnancy.
Side Effect:
Possible: Pain at the site of P/C administration in the form of mild pain of a breaking character (like overtrained muscle) and hyperemia. For b/m and p/k applications in high doses (more than 1,000,000 IU) - influenza-like syndrome (headache, weakness, fever, joint pain).
Contraindications for use:
Increased sensitivity to gamma interferon; pregnancy.
For Introduction: autoimmune diseases, diabetes mellitus.
For intranasal introduction Ingaron: children under 7 years of age
Side Effects Ingaron
Not marked.
Conditions of leave from pharmacies and storage periods
The drug Ingaron should be stored in a dry, dark place, at a temperature not higher than +25 ° C.
The solution of the drug Ingaron should be stored for no more than 10 days in the refrigerator (do not freeze).
Keep out of reach of children.
Shelf life 2 years.
After preparing the solution for 10 days.
Do not use after expiration date.
Over the counter.
Nosology Ingaron (ICD codes)
A15
Respiratory tuberculosis confirmed bacteriologically and histologically
B18.0
Chronic viral hepatitis B with delta agent
B18.1
Chronic viral hepatitis B without delta agent
B18.2
Chronic viral hepatitis C
B24
Human immunodeficiency virus [HIV], unspecified
D71
Functional disturbances of polymorphic-nuclear neutrophils
J09
Influenza caused by an identified zoonotic or pandemic influenza virus
J10
Influenza caused by an identified seasonal influenza virus
Z29.8
Other specific preventive measures
